logo
Nearly 19,000 Pounds of Deli Meats and Sausages Recalled Over Dangerous Sodium Nitrite Levels

Nearly 19,000 Pounds of Deli Meats and Sausages Recalled Over Dangerous Sodium Nitrite Levels

Yahoo01-05-2025

The Food Safety and Inspection Service (FSIS) announced a recall on April 29 for nearly 19,000 pounds of ready-to-eat sausage and sliced meat and poultry products produced by Smith Packing in Utica, New York, due to excessive sodium nitrite levels.
The recall was prompted by consumer complaints about off-tasting and discolored meats produced between February 19 and April 24, 2025.
Although no adverse health reactions have been confirmed, excessive sodium nitrite can cause methemoglobinemia — a condition impairing oxygen transport — which may lead consumers to experience serious health issues.It's time to check your fridge for another recall.
On April 29, the Food Safety and Inspection Service (FSIS) posted a recall notice for Smith Packing, LLC, based in Utica, N.Y., which is recalling 18,792 pounds of ready-to-eat sausage and sliced meat and poultry products due to their excessive sodium nitrite levels.
As WebMD explained, sodium nitrate is a "yellowish-white, odorless powder" that can be found in small amounts in certain foods, often used to preserve them and enhance flavors. However, in excessive amounts, WebMD added, it can "lower the ability of your red blood cells to move oxygen. Doctors refer to this harmful condition as methemoglobinemia. This can affect your ability to breathe, which can cause you to collapse. Very high levels of sodium nitrite can kill you."
According to the recall notice, the issue was discovered after the company informed FSIS about it following consumer complaints that the product tasted "off" and appeared off-color.
Related: Hospitalizations and Deaths From Contaminated Food Doubled in 2024 — Here's Everything You Need to Know
The company's ready-to-eat sausage and sliced meat and poultry items were produced on various dates, according to the recall, between February 19, 2025, and April 24, 2025. All products have the establishment number 'EST. 4578' or 'P-4578' printed inside the USDA mark of inspection. The recalled items were shipped to institutional and retail locations across New York State. (You can view the recalled product labels here.)
The full product list includes the following:
As-Salaam Beef Breakfast Sausage
As-Salaam Beef Frank Halal
Smith Packing Beef Knockwurst
As-Salaam Beef Smoked Sausage
Honest John Bratwurst
Honest John Breakfast Sausage/ Brown and Serve
Smith Packing Export Bologna
Smith Packing Export Salami
Honest John HJ Jumbo Franks
Honest John Polish Sausage
As-Salaam Hot Roasted Chicken Sausage Garlic
As-Salaam Roasted Chicken Sausage Grilled
Smith Packing NYS Beef Bologna
Beefland USA Regular Beef Sausage
Honest John Retail HJ Polish
The good news is that there have been no confirmed reports of adverse reactions resulting from the consumption of these products, according to the company and the FSIS. However, if you have consumed one of the products and feel unwell, the FSIS urges you to contact your doctor immediately.In a statement to USA Today, Palmer Foods stated, "In coordination with the USDA, Smith agreed to a recall covering about 18,000 pounds of meat products labeled as Honest John's, As-Salam, and Beefland that may have been affected." It added that, " Approximately 90% of that product never left the warehouse, and approximately 34 customers were identified who received potentially inedible meats. Palmer is working with those customers to recover and destroy any potentially affected product."
While many products may be off store shelves, the FSIS noted it's "concerned that some products may be in institutional and consumers' refrigerators or freezers," so it is asking people to also check any backstock. Moreover, if you still have some, the FSIS noted that those "who have purchased these products are urged not to consume or use them. These products should be thrown away or returned to the place of purchase."
Anyone with a question on this recall can contact Joe Schaeffer, the director of marketing at Palmer Foods, at jschaeffer@palmerfoods.com.Company issuing recall: Smith PackingReason for recall: excessive sodium nitrite levelsBrands affected: As-Salaam Beef Breakfast Sausage, As-Salaam Beef Frank Halal, Smith Packing Beef Knockwurst, As-Salaam Beef Smoked Sausage, Honest John Bratwurst, Honest John Breakfast Sausage Brown and Serve, Smith Packing Export Bologna, Smith Packing Export Salami, Honest John HJ Jumbo Franks, Honest John Polish Sausage, As-Salaam Hot Roasted Chicken Sausage Garlic, As-Salaam Roasted Chicken Sausage Grilled, Smith Packing NYS Beef Bologna, Beefland USA Regular Beef Sausage, Honest John Retail HJ PolishEstablishment numbers: 'EST. 4578' or 'P-4578'Amount of products affected: 18,792 poundsStates affected: New York Brand labels: Concerned consumers should check for images of recalled brands on the FSIS websiteRead the original article on Food & Wine

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Medical Zeolite: Benefits and Applications of Lavavitae and Lava Pure
Medical Zeolite: Benefits and Applications of Lavavitae and Lava Pure

Time Business News

timea day ago

  • Time Business News

Medical Zeolite: Benefits and Applications of Lavavitae and Lava Pure

Medical zeolite, or Zeolit medyczny in Polish, has garnered significant attention in the health and wellness world due to its remarkable detoxifying properties and natural healing potential. This unique mineral, formed from volcanic ash and alkaline groundwater, offers a powerful tool for removing toxins and heavy metals from the body. Among the many brands utilizing this extraordinary mineral, Lavavitae and Lava Pure stand out as pioneers in delivering high-quality medical zeolite supplements designed to support holistic health. These products harness the natural benefits of zeolite in a purified and bioavailable form, making them accessible for everyday health maintenance. Understanding the impact of medical zeolite on the human body and the innovations behind Lavavitae and Lava Pure products is essential for anyone interested in natural health solutions. These brands have successfully combined scientific research with nature's gift to provide consumers with safe, effective ways to improve detoxification, boost immunity, and enhance overall wellbeing. In this article, we will explore the multifaceted benefits of Zeolit medyczny, delve into the specific qualities of Lavavitae and Lava Pure, and examine how these products can be integrated into modern wellness routines. What is Medical Zeolite? Medical zeolite is a crystalline aluminosilicate mineral known for its porous structure and strong negative charge. This molecular composition enables zeolite to trap positively charged toxins, heavy metals, and harmful substances inside its lattice framework. As a result, it acts as a natural detoxifier, effectively cleansing the body of pollutants that contribute to chronic diseases and impaired health. The most commonly used form of zeolite in medicine and supplements is clinoptilolite, prized for its safety and efficacy. Unlike many synthetic detox agents, Zeolit medyczny is non-toxic and gentle on the body, making it suitable for long-term use. The ability of medical zeolite to selectively capture harmful molecules while leaving beneficial minerals intact sets it apart in the field of natural health supplements. This selective absorption not only detoxifies but can also improve nutrient absorption, support gut health, and reduce oxidative stress. The Science Behind Lavavitae and Lava Pure Lavavitae and Lava Pure represent two of the most reputable brands that have revolutionized the use of medical zeolite in dietary supplements. Both brands focus on sourcing pure volcanic minerals, refining them to pharmaceutical-grade standards, and ensuring maximum bioavailability for consumers. Their rigorous purification processes remove impurities and enhance the mineral's natural properties, making the zeolite safe and effective for internal use. Lavavitae emphasizes its commitment to natural wellness, providing a product free from additives, fillers, or synthetic chemicals. The company's focus on quality control and transparency has earned it trust among health enthusiasts and practitioners alike. Meanwhile, Lava Pure boasts a patented purification method that guarantees the highest concentration of active zeolite particles, delivering superior detoxification benefits with every dose. Both Lavavitae and Lava Pure products have been extensively studied and tested, with users reporting improved energy levels, reduced inflammation, and enhanced detoxification support. These brands highlight the importance of medical zeolite in modern health regimens, especially for those exposed to environmental toxins or seeking natural ways to maintain optimal health. Health Benefits of Zeolit Medyczny in Detoxification One of the primary benefits of Zeolit medyczny lies in its potent detoxification ability. In today's environment, exposure to heavy metals such as lead, mercury, and cadmium is common, whether through polluted air, contaminated water, or certain foods. Over time, these toxic substances accumulate in the body and can lead to serious health issues including neurological damage, immune dysfunction, and chronic inflammation. Lavavitae and Lava Pure utilize medical zeolite to bind these heavy metals and facilitate their safe removal from the body. The negatively charged zeolite attracts and traps positively charged toxins, preventing their reabsorption and allowing for natural elimination through excretion. This detoxification process can help reduce the burden on the liver and kidneys, organs responsible for filtering waste from the bloodstream. Moreover, regular use of medical zeolite supplements has been linked to improved gut health. By adsorbing harmful bacteria and toxins in the digestive tract, Zeolit medyczny can promote a balanced microbiome and reduce symptoms of digestive discomfort. This dual action of detoxifying and supporting gut function positions Lavavitae and Lava Pure as valuable allies in comprehensive wellness strategies. Immune Support and Antioxidant Properties Beyond detoxification, medical zeolite exhibits properties that can bolster the immune system and reduce oxidative stress, both of which are crucial for maintaining long-term health. The immune-enhancing effects stem partly from zeolite's ability to reduce toxic load, which otherwise can suppress immune function and increase vulnerability to infections and chronic illnesses. Lavavitae and Lava Pure's formulations capitalize on these benefits, offering consumers a natural means to strengthen their body's defenses. Additionally, zeolite's antioxidant activity helps neutralize free radicals—unstable molecules that cause cellular damage and accelerate aging. By scavenging these harmful agents, medical zeolite supports cellular repair and reduces inflammation. These immune-supporting effects are particularly valuable in today's fast-paced and polluted world, where oxidative stress and immune challenges are more prevalent. Incorporating Zeolit medyczny from trusted brands like Lavavitae and Lava Pure into a daily routine can provide a protective shield that promotes resilience and vitality. How to Incorporate Lavavitae and Lava Pure Into Your Wellness Routine Integrating medical zeolite supplements such as Lavavitae and Lava Pure into daily health regimens is straightforward and convenient. Both products are available in powder or capsule form, allowing users to choose the format that best fits their lifestyle. Typically, these supplements are taken with water on an empty stomach to maximize absorption and effectiveness. Consistency is key when using Zeolit medyczny for detox and health support. Regular use over several weeks or months can yield noticeable improvements in energy, digestion, and overall wellbeing. It's important to follow recommended dosages and consult with a healthcare professional, especially for individuals with pre-existing conditions or those taking medications. In addition to supplementation, combining medical zeolite use with a balanced diet, proper hydration, and regular exercise enhances its benefits. Lavavitae and Lava Pure products fit seamlessly into holistic wellness approaches that prioritize natural, safe, and sustainable health solutions. Why Choose Lavavitae and Lava Pure for Medical Zeolite? When selecting a medical zeolite supplement, quality, purity, and bioavailability are paramount. Lavavitae and Lava Pure excel in all these areas, offering consumers confidence that they are receiving premium products that deliver real health benefits. Their commitment to rigorous testing and sustainable sourcing ensures that every batch meets high standards. Moreover, these brands invest in research and innovation to improve the efficacy of their formulations. This dedication results in supplements that are not only effective but also easy to use and well-tolerated by the body. For those looking to experience the full potential of Zeolit medyczny, Lavavitae and Lava Pure represent trusted choices in a crowded marketplace. Beyond product quality, both brands also provide educational resources and customer support to guide users in maximizing the benefits of medical zeolite. This holistic approach helps build a community of informed consumers who prioritize their health through natural means. Embracing Natural Healing with Medical Zeolite The growing interest in natural health remedies has brought Zeolit medyczny into the spotlight as a versatile and powerful mineral supplement. Lavavitae and Lava Pure have played crucial roles in popularizing medical zeolite by making it accessible, safe, and effective for a wide audience. As more research uncovers the potential of medical zeolite in detoxification, immune support, and cellular protection, these products continue to gain recognition as essential components of modern wellness strategies. Embracing medical zeolite through trusted brands like Lavavitae and Lava Pure empowers individuals to take proactive steps towards better health, using nature's own tools to combat today's environmental challenges. Incorporating medical zeolite into your lifestyle is not just a trend but a meaningful choice toward sustained vitality and resilience. Whether you are seeking to cleanse your body, boost your immune system, or simply maintain balance in a toxin-filled world, Lavavitae and Lava Pure provide reliable solutions grounded in science and tradition. TIME BUSINESS NEWS

Ionis doses first subject in Phase III trial of Angelman syndrome therapy
Ionis doses first subject in Phase III trial of Angelman syndrome therapy

Yahoo

time4 days ago

  • Yahoo

Ionis doses first subject in Phase III trial of Angelman syndrome therapy

Ionis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582, aimed at treating individuals with Angelman syndrome (AS), a rare neurodevelopmental disorder. The placebo-controlled, double-blind trial will recruit nearly 200 AS adults and children with a maternal UBE3A gene deletion or mutation. Over a 52-week treatment period, subjects will be randomised in a 2:1 ratio and given either the therapy or a placebo. Quarterly doses of either 40mg or 80mg of ION582 will be administered to those in the active treatment groups. After the initial treatment phase, eligible subjects will have the opportunity to enter a long-term extension segment of the trial, where the therapy will be administered for up to two years. The primary goal of the trial is to assess improvements in expressive communication using the Bayley Scales for Infant and Toddler Development-4 (Bayley-4), a direct clinician-administered assessment tool. Expressive communication deficits are notably the most burdensome symptoms for caregivers of individuals with AS. The trial will also evaluate secondary endpoints, including overall disease severity, communication, cognition, motor functioning, sleep, and daily living skills, as well as other exploratory endpoints. ION582 has previously shown promise in the multiple ascending dose (MAD) portion of the Phase I/II open-label HALOS trial, demonstrating clinical improvement across various functional domains such as cognition, motor function, and communication. The RNA-targeted antisense medicine, ION582, works by inhibiting the expression of the UBE3A antisense transcript (UBE3A-ATS) to potentially increase the UBE3A protein production, to treat AS. Ionis Pharmaceuticals neurology senior vice-president Holly Kordasiewicz: 'This placebo-controlled study will evaluate ION582 in both children and adults with either UBE3A deletion or mutation and builds on earlier encouraging findings from our Phase I/II HALOS study. 'With ION582, we continue to advance our leading wholly owned neurology pipeline, which includes eight medicines in clinical development across a range of rare and more prevalent diseases.' Last year, Ionis announced the design for the Phase III trial of ION582 for the treatment of AS, following discussions with the US Food and Drug Administration. "Ionis doses first subject in Phase III trial of Angelman syndrome therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

Business Wire

time5 days ago

  • Business Wire

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to evaluate the efficacy and safety of ION582, an investigational medicine for the treatment of people living with Angelman syndrome (AS), a serious and rare neurodevelopmental disorder that leads to significant physical and cognitive impairments. 'Dosing the first person with Angelman syndrome in our pivotal REVEAL study marks an important milestone for this underserved community, who currently have no approved disease modifying treatments,' said Holly Kordasiewicz, Ph.D., senior vice president of neurology, Ionis. 'This placebo-controlled study will evaluate ION582 in both children and adults with either UBE3A deletion or mutation and builds on earlier encouraging findings from our Phase 1/2 HALOS study. This milestone reflects our commitment to those impacted by Angelman syndrome and builds on our legacy of innovation in neurology including the development of SPINRAZA and QALSODY. With ION582, we continue to advance our leading wholly owned neurology pipeline, which includes eight medicines in clinical development across a range of rare and more prevalent diseases.' REVEAL (NCT06914609) is a global, randomized, double-blind, placebo-controlled Phase 3 study that will enroll approximately 200 children and adults with AS that have a maternal UBE3A gene deletion or mutation. During the 52-week treatment period, participants will be randomized 2:1 to receive either ION582 or placebo. Participants in the active treatment groups will receive quarterly 40 mg or 80 mg doses of ION582. Following the treatment period, eligible participants will transition into the long-term extension portion of the study where all participants will receive ION582 for up to 2 years. The primary endpoint is improvement in expressive communication as assessed by the Bayley Scales for Infant and Toddler Development-4 (Bayley-4), an objective and direct clinician-administered assessment of clinical functioning. Deficits in expressive communication are reported to be the symptoms most challenging to caregivers of people with AS. Secondary endpoints include overall disease severity, cognition, communication, sleep, motor functioning and daily living skills, in addition to other exploratory endpoints. In the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label HALOS study, ION582 provided consistent and encouraging clinical improvement on all functional domains including communication, cognition and motor function and showed favorable safety and tolerability at all dose levels in the study. For more information on the REVEAL clinical study, please visit and About ION582 ION582 is an investigational RNA-targeted antisense medicine designed to inhibit the expression of the UBE3A antisense transcript (UBE3A-ATS) and increase production of UBE3A protein, for the potential treatment of Angelman syndrome (AS). The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) granted Orphan Drug designation to ION582. Additionally, the FDA granted Fast Track and Rare Pediatric designations to ION582. About Angelman Syndrome (AS) AS is a rare, genetic neurological disease that affects an estimated 1 in 21,000 people worldwide and is caused by the loss of function of the maternally inherited UBE3A gene. AS typically presents in infancy and is characterized by profound intellectual disability, balance issues, motor impairment and debilitating seizures. Most people with AS are unable to speak. Individuals with AS have a normal lifespan but require complete care from a caregiver. Some symptoms can be managed with existing medicines; however, there are no approved disease modifying therapies. About Ionis Neurology Ionis has been at the forefront of discovering and developing leading neurological disease medicines, including SPINRAZA ® (nusinersen), the first approved treatment for spinal muscular atrophy, WAINUA™ (eplontersen), a medicine to treat hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), and QALSODY ® (tofersen) for SOD1-ALS. The clinical-stage portfolio includes 13 therapies, of which eight are wholly owned by Ionis. Ionis' investigational portfolio includes medicines for which there are few or no disease modifying treatments, such as rare diseases including Prion disease and Alexander disease and more common conditions such as Alzheimer's and Parkinson's disease. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit and follow us on X (Twitter), LinkedIn and Instagram. Ionis Forward-looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of ION582, our commercial medicines, additional medicines in development and technologies. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2024, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company. In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our" and "us" all refer to Ionis Pharmaceuticals and its subsidiaries. Ionis Pharmaceuticals ® is a trademark of Ionis Pharmaceuticals, Inc. SPINRAZA ® and QALSODY ® are registered trademarks of Biogen. WAINUA™ is a registered trademark of the AstraZeneca group of companies.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store